Ocular Therapeutix, Inc.
Index- P/E- EPS (ttm)-0.43 Insider Own0.40% Shs Outstand76.76M Perf Week6.05%
Market Cap416.67M Forward P/E- EPS next Y-0.71 Insider Trans65.07% Shs Float75.85M Perf Month-19.04%
Income-32.50M PEG- EPS next Q-0.18 Inst Own58.50% Short Float3.83% Perf Quarter-3.52%
Sales49.90M P/S8.35 EPS this Y96.70% Inst Trans-0.25% Short Ratio3.84 Perf Half Y-14.95%
Book/sh0.86 P/B5.09 EPS next Y16.50% ROA-16.60% Target Price15.79 Perf Year-55.03%
Cash/sh1.41 P/C3.10 EPS next 5Y- ROE-40.50% 52W Range2.91 - 12.50 Perf YTD-37.16%
Dividend- P/FCF- EPS past 5Y45.60% ROI-56.00% 52W High-64.96% Beta1.37
Dividend %- Quick Ratio6.10 Sales past 5Y87.30% Gross Margin90.20% 52W Low50.52% ATR0.47
Employees228 Current Ratio6.10 Sales Q/Q5.10% Oper. Margin- RSI (14)40.92 Volatility15.69% 9.96%
OptionableYes Debt/Eq0.00 EPS Q/Q-120.00% Profit Margin-65.10% Rel Volume0.90 Prev Close4.41
ShortableYes LT Debt/Eq0.80 EarningsAug 08 AMC Payout- Avg Volume757.11K Price4.38
Recom1.90 SMA20-19.76% SMA50-16.12% SMA200-10.43% Volume679,757 Change-0.68%
Aug-10-22Resumed Berenberg Buy $15
Aug-10-21Upgrade H.C. Wainwright Neutral → Buy $17
Dec-28-20Downgrade H.C. Wainwright Buy → Neutral
Dec-17-20Initiated Berenberg Buy $27
Nov-13-20Reiterated Raymond James Strong Buy $15 → $25
Aug-10-20Reiterated H.C. Wainwright Buy $10 → $13
Mar-03-20Upgrade Raymond James Outperform → Strong Buy
May-21-19Reiterated H.C. Wainwright Buy $12 → $9
May-21-19Downgrade Raymond James Strong Buy → Outperform $11 → $5
May-21-19Downgrade Cowen Outperform → Market Perform $13 → $3
Dec-03-18Reiterated Cantor Fitzgerald Overweight $22 → $24
Nov-15-18Initiated Raymond James Strong Buy $10
Sep-07-18Initiated Piper Jaffray Overweight
Oct-24-17Initiated Guggenheim Buy $12
Jul-26-17Initiated H.C. Wainwright Buy $10
Jul-12-17Reiterated Cantor Fitzgerald Overweight $35 → $21
Jun-23-17Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-10-17Initiated Cantor Fitzgerald Overweight $35
Nov-15-16Reiterated RBC Capital Mkts Outperform $30 → $32
Aug-11-16Initiated JMP Securities Mkt Outperform
Sep-30-22 09:27AM
Sep-27-22 10:21AM
Sep-22-22 07:00AM
Sep-07-22 04:01PM
08:00AM Loading…
Aug-10-22 08:00AM
Aug-08-22 05:45PM
Jul-25-22 08:00AM
Jul-13-22 01:58PM
Jun-13-22 01:23PM
Jun-08-22 07:00AM
Jun-01-22 08:00AM
May-13-22 06:03AM
May-09-22 05:45PM
04:01PM Loading…
May-03-22 05:35PM
Apr-26-22 08:00AM
Apr-25-22 08:00AM
Apr-14-22 04:35PM
Apr-12-22 10:46PM
Mar-04-22 08:00AM
Mar-02-22 07:28AM
Feb-28-22 05:35PM
Feb-23-22 06:05PM
Feb-22-22 08:00AM
Feb-11-22 08:00AM
Jan-18-22 08:00AM
09:38AM Loading…
Jan-12-22 09:38AM
Jan-04-22 08:00AM
Dec-06-21 07:00AM
Nov-20-21 06:09AM
Nov-15-21 08:00AM
Nov-09-21 01:17PM
Nov-08-21 07:35PM
Nov-05-21 11:44AM
Nov-01-21 08:00AM
Oct-29-21 04:01PM
Oct-28-21 03:05PM
Oct-25-21 03:13PM
Oct-24-21 10:00AM
Oct-22-21 03:30PM
Oct-17-21 08:35PM
Oct-11-21 12:30PM
Sep-28-21 08:00AM
Sep-22-21 08:00AM
Sep-13-21 06:45AM
Sep-07-21 08:00AM
Sep-06-21 12:18PM
Aug-22-21 07:38AM
Aug-21-21 06:21AM
Aug-10-21 08:00AM
Aug-09-21 05:25PM
Aug-05-21 04:01PM
Aug-02-21 03:01PM
Jul-29-21 08:00AM
Jul-28-21 08:00AM
Jul-27-21 10:00AM
Jul-23-21 08:00AM
Jul-22-21 04:01PM
Jul-11-21 08:43AM
Jul-06-21 06:44AM
Jun-29-21 08:00AM
May-26-21 08:00AM
May-20-21 08:46AM
May-07-21 02:12AM
May-05-21 04:01PM
May-03-21 06:16PM
Apr-28-21 08:00AM
Apr-20-21 06:02AM
Apr-01-21 09:21AM
Mar-11-21 05:25PM
Mar-05-21 08:15AM
Mar-04-21 04:01PM
Mar-01-21 07:00AM
Feb-25-21 08:00AM
Feb-24-21 08:00AM
Feb-19-21 04:49AM
Feb-17-21 07:56AM
Feb-16-21 06:55AM
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUMMER ROAD LLC10% OwnerSep 29Buy4.0418,80075,9886,094,761Sep 29 07:51 PM
SUMMER ROAD LLC10% OwnerSep 28Buy4.101,2004,9206,075,961Sep 29 07:51 PM
SUMMER ROAD LLC10% OwnerSep 27Buy4.68130,000608,3226,074,761Sep 29 07:51 PM
LINDSTROM RICHARD L MDDirectorMay 12Option Exercise1.229,46911,55299,469May 16 04:13 PM
SUMMER ROAD LLC10% OwnerFeb 23Buy4.8010,00047,9865,944,761Feb 23 05:08 PM
SUMMER ROAD LLC10% OwnerFeb 18Buy5.0040,000199,9405,934,761Feb 23 05:08 PM
SUMMER ROAD LLC10% OwnerJan 28Buy5.204,02320,9205,894,761Jan 31 07:00 PM
SUMMER ROAD LLC10% OwnerJan 27Buy5.201,4777,6805,890,738Jan 31 07:00 PM
SUMMER ROAD LLC10% OwnerJan 24Buy5.3144,400235,8935,889,261Jan 24 05:19 PM
SUMMER ROAD LLC10% OwnerJan 21Buy5.5612,15267,5315,844,861Jan 24 05:19 PM
SUMMER ROAD LLC10% OwnerJan 20Buy5.7017,948102,3845,832,709Jan 24 05:19 PM
SUMMER ROAD LLC10% OwnerJan 18Buy6.006,80740,8275,814,761Jan 18 05:30 PM
SUMMER ROAD LLC10% OwnerJan 14Buy6.0333,193200,1115,807,954Jan 18 05:30 PM
SUMMER ROAD LLC10% OwnerJan 13Buy6.2010,00061,9835,774,761Jan 18 05:30 PM
SUMMER ROAD LLC10% OwnerDec 15Buy6.2215,00093,2465,764,761Dec 16 05:05 PM
SUMMER ROAD LLC10% OwnerDec 14Buy6.4129,490189,1755,749,761Dec 16 05:05 PM
SUMMER ROAD LLC10% OwnerDec 13Buy6.5010,51068,3025,720,271Dec 14 07:28 PM
SUMMER ROAD LLC10% OwnerDec 10Buy6.6530,000199,4945,709,761Dec 14 07:28 PM
SUMMER ROAD LLC10% OwnerDec 08Buy6.755,30035,7755,679,761Dec 08 06:05 PM
SUMMER ROAD LLC10% OwnerDec 06Buy6.1355,600340,8285,674,461Dec 08 06:05 PM